Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
View Top Employees from Aurealis TherapeuticsWebsite | https://aurealistherapeutics.com/ |
Revenue | $6.2 million |
Employees | 17 (12 on RocketReach) |
Founded | 2015 |
Phone | +358 45 8433550 |
Technologies |
JavaScript,
HTML,
PHP
+5 more
(view full list)
|
Industry | Biotechnology Research, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Health Care, Medical, Pharmaceutical |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Aurealis Therapeutics employee's phone or email?
The Aurealis Therapeutics annual revenue was $6.2 million in 2024.
Haritha Samaranayake is the Chief Medical Officer of Aurealis Therapeutics.
12 people are employed at Aurealis Therapeutics.
The NAICS codes for Aurealis Therapeutics are [325, 32, 32541, 3254].
The SIC codes for Aurealis Therapeutics are [283, 28].